In-hospital cardiovascular outcomes of COVID-19-associated cytokine storm: a population-level study
Frontiers in Epidemiology · 03.06.2026 · 6
DOI: 10.3389/fepid.2026.1836720 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Epidemiology, online erschienen am 03.06.2026. Verfasst von Rajveer Sagoo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sathyamoorthy Lab, Department of Internal Medicine, Burnett School of Medicine at Texas, Christian University, Fort Worth, TX, United States. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
In severe COVID-19, hyperinflammatory “Cytokine Storm” (CS) can escalate disease severity, yet large-scale data on its cardiovascular impacts remain limited.
Objective
To assess the influence of CS severity on in-hospital cardiovascular outcomes and mortality in COVID-19 patients.
Methods
A retrospective analysis of the 2021 National Inpatient Sample (NIS) was performed, including adults (≥18 years) hospitalized with a principal COVID-19 diagnosis (ICD-10: U07.1), while excluding other hyperinflammatory conditions. CS was identified and categorized into four severity grades (ICD-10: D89.83). Multivariable logistic regression was utilized to assess associations between CS severity and in-hospital outcomes.
Results
In a weighted cohort of 1,428,892 hospitalized adults with COVID-19, 15,290 (1.1%) had CS. Mortality rose from 8.3% in non-CS patients to 26.9% in grade 4 (adjusted odds ratio [aOR] 3.334; 95% CI [2.810–3.956]), accompanied by increases in cardiac arrest (1.7%–4.4%; aOR 1.742; [1.234–2.459]) and venous thromboembolism (4.8%–9.4%; aOR 1.739; [1.369–2.210]) ( p all < 0.05). Myocardial Infarction (non-CS: 3.3% vs. Grade 4: 3.1%) and Cardiac Arrhythmias (non-CS: 14.4% vs. grade 4: 14.4%) remained similar across groups but showed decreased adjusted odds in grade 2 (aOR 0.328 [0.221–0.488]; aOR 0.738 [0.641–0.850]) ( p all < 0.05). Heart failure incidence declined with advancing CS grade (non-CS: 13.5% vs. grade 4: 12.5%), with grades 1 and 2 showing reduced odds (aOR 0.651; [0.475–0.892]), (aOR 0.702; [0.584–0.845]) ( p all < 0.05). Cardiogenic shock, Ischemic CVA, and Transient Ischemic attack were infrequent and excluded from graded analyses. Compared with non-CS patients, those with grade 4 had a longer median length of stay (5 days vs. 11 days) and higher median total cost (US $44,363 vs. US $142,280) ( p all < 0.05).
Conclusion
Within this cohort, advanced CS demonstrated an association with increased mortality and select cardiovascular complications in hospitalized COVID-19 patients; Moreover, certain events, such as arrhythmias and heart failure, showed nuanced patterns, underscoring the complex interplay between hyperinflammation and cardiac pathophysiology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sathyamoorthy Lab, Department of Internal Medicine, Burnett School of Medicine at Texas, Christian University, Fort Worth, TX, United States.
- College of Science and Engineering, Texas Christian University, Fort Worth, TX, United States.
- University of Tennessee-Chattanooga/Erlanger Health System, Chattanooga, TN, United States.
- Consultants in Cardiovascular Medicine and Science, Fort Worth, TX, United States.
Zitieren
APA
Sagoo, R., Sagoo, N. S., Murdock, P., & Sathyamoorthy, M. (2026). In-hospital cardiovascular outcomes of COVID-19-associated cytokine storm: a population-level study. Frontiers in Epidemiology, 6. https://doi.org/10.3389/fepid.2026.1836720
Vancouver
Sagoo R, Sagoo NS, Murdock P, Sathyamoorthy M. In-hospital cardiovascular outcomes of COVID-19-associated cytokine storm: a population-level study. Frontiers in Epidemiology. 2026;6. doi:10.3389/fepid.2026.1836720
BibTeX
@article{Sagoo2026,
author = {Sagoo, Rajveer and Sagoo, Navraj S and Murdock, Paul and Sathyamoorthy, Mohanakrishnan},
title = {In-hospital cardiovascular outcomes of COVID-19-associated cytokine storm: a population-level study},
journal = {Frontiers in Epidemiology},
year = {2026},
volume = {6},
doi = {10.3389/fepid.2026.1836720}
}
EUVIMED